Q32 Bio Inc.

Today we reported fourth quarter 2025 financial results and provided a corporate update. Learn more: bit.ly/40rlvyq $QTTB

We look forward to participating in the @Oppenheimer 36th Annual Healthcare Life Sciences Conference next week. Tune in to our fireside chat on Wednesday, February 25th at 2:00 p.m. ET. More details here: bit.ly/4cG2SxQ

Maria Marzilli has been appointed Chief Business Officer of Q32 Bio! Having been with the Company since 2019, Maria will continue to be instrumental in guiding BD as we work to advance therapies for #alopeciaareata and other #autoimmunediseases.

Today we reported third quarter 2025 financial results and provided a corporate update. Learn more: bit.ly/4qWo6MR $QTTB

We are excited to announce that we have completed enrollment and exceeded our enrollment target in Part B of our SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe #alopeciaareata (AA). Learn more: bit.ly/42SJoRb

We look forward to participating in a fireside chat at the 2025 @WellsFargo Healthcare Conference next week in Boston. Find webcast details here: bit.ly/3HQ79lw #biotech #alopeciaareata #autoimmunediseases

Today we reported second quarter 2025 financial results and provided a corporate update. Learn more: bit.ly/3Hm8TTd $QTTB

July is #InternationalWomenWithAlopeciaMonth, a time to raise awareness for #alopeciaareata (AA) and its impact on women. Our lead candidate, bempikibart, is currently being evaluated in our SIGNAL-AA Phase 2a clinical trial for AA. Learn more: bit.ly/3TN6T9i

We enjoyed connecting with the #alopeciaareata community at the @NAAF_org 40th Annual Conference. Thanks to #NAAF for an insightful event, and to everyone who stopped by our booth to learn more about our SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata.

We’re at the @NAAF_org 40th Annual Conference in Chicago! Attending #NAAF40Conf? Visit our booth to grab a sweet treat and learn more about our ongoing SIGNAL-AA Phase 2a clinical trial of bempikibart, a fully human anti-IL-7Rα antibody, for #alopeciaareata.

We’re excited to attend the upcoming @NAAF_org 40th Annual Conference, the world’s largest gathering of individuals with #alopeciaareata. If you’re attending, stop by our booth to chat with our team and pick up a company gift bag! #NAAF40Conf

Today we reported first quarter 2025 financial results and provided a corporate update. Learn more: bit.ly/3RWjRke $QTTB

We are pleased to announce that the U.S. FDA has granted Fast Track designation to bempikibart, a fully human anti-IL-7Rα antibody currently being evaluated in a Phase 2 program, for the treatment of #alopeciaareata. Learn more: bit.ly/3GwRFC1

We are excited to announce that we have dosed the first patients in both the Part A open-label extension (OLE) and Part B of our SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with #alopeciaareata. Learn more: bit.ly/4lzDrjK

Today we presented additional results from Part A of our SIGNAL-AA Phase 2a clinical trial of bempikibart demonstrating encouraging activity in patients with #alopeciaareata (AA) at the 2025 @AADskin Meeting in Orlando. Learn more: bit.ly/41Qi6KQ #AAD2025

Today @Q32Bio reported Q3 '24 results and provided our corporate update. To view our most recent press release and learn more, please visit q32bio.com. #Q32Bio #QTTB

Q32 Bio Inc. will be at this year's American Society of Nephrology Kidney Week to highlight data from completed Phase 1 clinical trial of ADX-097 supporting continued clinical advancement. To view our press release, please visit q32bio.com. #ASN2024 #Q32Bio #QTTB

October is Eczema Awareness Month and Q32 Bio Inc. is raising awareness of atopic dermatitis. Visit us at Q32bio.com to learn more. #AtopicDermatitis #EczemaAwarenessMonth #Q32Bio #QTTB

@Citeline @Q32Bio is so proud of our CEO, Jodie Morrison (She/Her), for being named as a finalist for Scrip’s Executive of the Year Award!

The Scrip Awards shortlist has now been announced! 📢Visit our website to see who the 2024 finalists are! #ScripAwards ow.ly/VCTQ50Tl0mG